Idiopathic Pulmonary Fibrosis: Pipeline Assessment & Insights - ResearchAndMarkets.com

DUBLIN--()--The "Idiopathic Pulmonary Fibrosis: Pipeline Assessment and Insights" report has been added to ResearchAndMarkets.com's offering.

Disease Indication Overview:

This section highlights the basic definition, causes and symptoms of disease and details the types of Idiopathic Pulmonary Fibrosis disease. Further details on the profile of Idiopathic Pulmonary Fibrosis patients, Symptoms experienced by the patients, and disease progression in patients are outlined in the report.

Pipeline Analysis by Phases, Mechanism of Action and Novelty of Mechanism of Action:

This section of the report highlights and details the key products in development for Idiopathic Pulmonary Fibrosis disease area. The section mentions the products in different phases of development including the NDA/BLA Filing phase, Phase III, Phase II, Phase I, Pre-Clinical phase and the Discovery phase. The section also details the products which have been suspended or terminated during the trial stages of development.

Drugs Profile Overview:

The report, in this section, details all the promising therapies, in Idiopathic Pulmonary Fibrosis disease, in pipeline in different phases of development. The details of a promising drug in pipeline include a detailed overview about the drug in terms of its product details, mechanism of action, mode of administration etc. Further details include the research and development key milestones for the product, detailed information about the efficacy, safety and tolerability and dosage frequency and formulation of the drug.

Pipeline Covered:

NDA/BLA Filed

Phase III Pipeline

Phase II Pipeline

Phase I Pipeline

Preclinical Pipeline

Discovery Pipeline

Suspended and Terminated products

Pipeline analysis by Mechanism of Action

Pipeline Analysis by Novelty of Mechanism of Action

Companies Mentioned

  • GlaxoSmithKline
  • Boehringer Ingelheim
  • Samil Pharmaceutical
  • Adamas Pharmaceuticals
  • ACADIA Pharmaceuticals
  • Ipsen
  • Ono Pharmaceutical
  • Neurocrine Biosciences
  • Fosun International
  • BIAL
  • Eisai
  • Merck KGaA
  • CSL
  • Meiji Holdings
  • Zambon
  • Newron Pharmaceuticals
  • Valeo Pharma
  • US WorldMeds
  • Vernalis
  • Mylan
  • Cephalon
  • Grnenthal Gruppe
  • STADA Arzneimittel
  • Italfarmaco
  • Gen Ila
  • Sumitomo Dainippon Pharma
  • Cynapsus Therapeutics
  • Aquestive Therapeutics
  • Adagio Pharmaceuticals
  • Acorda Therapeutics
  • Civitas Therapeutics
  • Mitsubishi Tanabe Pharma
  • NeuroDerm
  • BioElectron Technology
  • Prothena

Key Topics Covered:

1 Table of Contents

2 Idiopathic Pulmonary Fibrosis Disease

3 Pipeline Assessment

4 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/t9s7cc/idiopathic?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Respiratory Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Respiratory Drugs